Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Rodríguez Escolar.
Fidalgo García ML, Rubio Cebrián S. Análisis costeefectividad de alendronato frente a placebo en la prevención de fractura de cadera.
Aten Primaria, 24 (1999), pp. 390-396
[2.]
D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, M.C. Nevitt, et al.
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
Lancet, 348 (1996), pp. 1535-1541
[3.]
S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barrett-Connor, T.A. Musliner, et al.
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial.
JAMA, 280 (1998), pp. 2077-2082
[4.]
D.M. Black, T.F. Reiss, M.C. Nevitt, J. Cauley, D. Karpf, S.R. Cummings.
Design of the Fracture Intervention Trial.
Osteoporosis Int, 3 (1993), pp. 29-39
[5.]
Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis, pp. 1-88
[6.]
A. Albarracín Serra, C. Gámiz de Luna.
Costes de la osteoporosis en España durante 1994 (tesina).
[7.]
E.W. Gregg, J.A. Cauley, D.G. Seeley, K.E. Ensrud, D.C. Bauer.
for the Study of Osteoporotic Fractures Research Group. Physical activity and osteoporotic fracture risk in older women.
Ann Intern Med, 129 (1998), pp. 81-88
[8.]
M.R. Law, N.J. Wald, T.W. Meade.
Strategies for prevention of osteoporosis and hip fracture.
Br Med J, 303 (1991), pp. 453-459
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
